BR112017002873A8 - Processo para preparar intermediários sintéticos para preparar derivados de tetra-hidroquinolina - Google Patents

Processo para preparar intermediários sintéticos para preparar derivados de tetra-hidroquinolina

Info

Publication number
BR112017002873A8
BR112017002873A8 BR112017002873A BR112017002873A BR112017002873A8 BR 112017002873 A8 BR112017002873 A8 BR 112017002873A8 BR 112017002873 A BR112017002873 A BR 112017002873A BR 112017002873 A BR112017002873 A BR 112017002873A BR 112017002873 A8 BR112017002873 A8 BR 112017002873A8
Authority
BR
Brazil
Prior art keywords
preparing
synthetic intermediates
derivatives
tetrahydroquinoline derivatives
preparation
Prior art date
Application number
BR112017002873A
Other languages
English (en)
Other versions
BR112017002873B1 (pt
BR112017002873A2 (pt
Inventor
Ford John
Paulus Gerardus Seerden Johannes
Ledru Amandine
Original Assignee
Dezima Pharma B V
Newamsterdam Pharma B V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51429345&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112017002873(A8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Dezima Pharma B V, Newamsterdam Pharma B V filed Critical Dezima Pharma B V
Publication of BR112017002873A2 publication Critical patent/BR112017002873A2/pt
Publication of BR112017002873A8 publication Critical patent/BR112017002873A8/pt
Publication of BR112017002873B1 publication Critical patent/BR112017002873B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

PROCESSO PARA PREPARAR INTERMEDIÁRIOS SINTÉTICOS PARA PREPARAR DERIVADOS DE TETRA-HIDROQUINOLINA. A presente invenção se refere a um processo para a preparação de intermediários sintéticos os quais podem ser usados na preparação de derivados de tetra-hidroquinclina, cujos derivados têm uma atividade inibidora contra proteína de transferência de colesteril (CETP), mostram efeitos de aumentar o nível de colesterol HDL e diminuir o nível de colesterol LDL , e podem ser usados para o tratamento e/ou prevenção de doenças, tais como doenças arterioscleróticas, hiperlipidemia, dislipidemia e semelhantes.
BR112017002873-5A 2014-08-12 2015-07-29 Processo para preparar intermediários sintéticos para preparar derivados de tetra-hidroquinolina BR112017002873B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
NLPCT/NL2014/050556 2014-08-12
NL2014050556 2014-08-12
PCT/NL2015/050555 WO2016024858A1 (en) 2014-08-12 2015-07-29 Process for preparing synthetic intermediates for preparing tetrahydroquinoline derivatives

Publications (3)

Publication Number Publication Date
BR112017002873A2 BR112017002873A2 (pt) 2018-07-17
BR112017002873A8 true BR112017002873A8 (pt) 2022-11-08
BR112017002873B1 BR112017002873B1 (pt) 2023-03-28

Family

ID=51429345

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017002873-5A BR112017002873B1 (pt) 2014-08-12 2015-07-29 Processo para preparar intermediários sintéticos para preparar derivados de tetra-hidroquinolina

Country Status (26)

Country Link
US (1) US10112904B2 (pt)
EP (2) EP4083022A1 (pt)
JP (1) JP6670310B2 (pt)
KR (1) KR102572626B1 (pt)
CN (1) CN107108558B (pt)
AR (1) AR101509A1 (pt)
AU (1) AU2015302407B2 (pt)
BR (1) BR112017002873B1 (pt)
CA (1) CA2958040C (pt)
CL (1) CL2017000367A1 (pt)
DK (1) DK3180314T3 (pt)
EA (1) EA034357B1 (pt)
ES (1) ES2926775T3 (pt)
HR (1) HRP20221061T1 (pt)
HU (1) HUE059947T2 (pt)
IL (1) IL250525B (pt)
LT (1) LT3180314T (pt)
MA (1) MA40378B1 (pt)
MX (1) MX367908B (pt)
PL (1) PL3180314T3 (pt)
PT (1) PT3180314T (pt)
RS (1) RS63575B1 (pt)
SG (1) SG11201701077XA (pt)
SI (1) SI3180314T1 (pt)
TW (1) TWI691490B (pt)
WO (1) WO2016024858A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112023017999A2 (pt) 2021-03-05 2023-11-14 Newamsterdam Pharma B V Obicetrapibe para tratamento de demências
EP4376832A1 (en) 2021-07-26 2024-06-05 NewAmsterdam Pharma B.V. Treatment of his hyporesponders
WO2023129595A1 (en) 2021-12-30 2023-07-06 Newamsterdam Pharma B.V. Obicetrapib and sglt2 inhibitor combination
WO2024009144A1 (en) 2022-07-05 2024-01-11 Newamsterdam Pharma B.V. Salts of obicetrapib and processes for their manufacture and intermediates thereof
WO2024042061A1 (en) 2022-08-22 2024-02-29 Newamsterdam Pharma B.V. Obicetrapib and ezetimibe combination treatment and fixed dose pharmaceutical compositions

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6197786B1 (en) * 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
RU2265010C2 (ru) * 2001-04-30 2005-11-27 Пфайзер Продактс Инк. Промежуточные соединения для ингибиторов cetp и способы их получения
UA90269C2 (ru) * 2004-04-02 2010-04-26 Мицубиси Танабе Фарма Корпорейшн Тетрагидрохинолиновые производные и способ их получения
TW200808731A (en) 2006-03-30 2008-02-16 Tanabe Seiyaku Co A process for preparing tetrahydroquinoline derivatives
CN101466679A (zh) * 2006-03-30 2009-06-24 田边三菱制药株式会社 制备四氢喹啉衍生物的方法

Also Published As

Publication number Publication date
BR112017002873B1 (pt) 2023-03-28
RS63575B1 (sr) 2022-10-31
AU2015302407B2 (en) 2019-09-19
MA40378A (fr) 2017-06-21
EA201790364A1 (ru) 2017-07-31
PT3180314T (pt) 2022-09-02
TW201613868A (en) 2016-04-16
AU2015302407A1 (en) 2017-03-02
BR112017002873A2 (pt) 2018-07-17
JP2017524742A (ja) 2017-08-31
MA40378B1 (fr) 2022-10-31
CA2958040A1 (en) 2016-02-18
WO2016024858A1 (en) 2016-02-18
MX367908B (es) 2019-09-11
CL2017000367A1 (es) 2018-02-09
CN107108558B (zh) 2019-11-19
IL250525A0 (en) 2017-03-30
EA034357B1 (ru) 2020-01-30
MX2017001930A (es) 2018-03-01
HUE059947T2 (hu) 2023-01-28
KR20170102204A (ko) 2017-09-08
EP4083022A1 (en) 2022-11-02
DK3180314T3 (da) 2022-08-29
US20170267640A1 (en) 2017-09-21
LT3180314T (lt) 2022-11-10
TWI691490B (zh) 2020-04-21
IL250525B (en) 2019-08-29
CA2958040C (en) 2022-09-13
EP3180314A1 (en) 2017-06-21
SI3180314T1 (sl) 2022-11-30
CN107108558A (zh) 2017-08-29
EP3180314B1 (en) 2022-06-22
US10112904B2 (en) 2018-10-30
AR101509A1 (es) 2016-12-21
HRP20221061T1 (hr) 2022-11-25
JP6670310B2 (ja) 2020-03-18
PL3180314T3 (pl) 2022-11-21
SG11201701077XA (en) 2017-03-30
KR102572626B1 (ko) 2023-08-30
ES2926775T3 (es) 2022-10-28

Similar Documents

Publication Publication Date Title
EA201790806A1 (ru) Иммунорегулирующие средства
MX2021006581A (es) Bacterias modificadas para tratar enfermedades asociadas con hiperamonemia.
EP3389725A4 (en) COMPOSITIONS AND METHOD FOR THE TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM
MX2020012046A (es) Ciclopropilamina como inhibidor de la desmetilasa 1 especifica de lisinas (lsd1).
EP3390634A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF EYE DISEASES
SG10201806846RA (en) Cyclopropylamines as lsd1 inhibitors
NZ724878A (en) Compounds and compositions as toll-like receptor 7 agonists
EP3119913A4 (en) Methods and compositions for treatment of immune-related diseases or disorders and/or therapy monitoring
EA201692177A1 (ru) Соединения и композиции в качестве агонистов toll-подобного рецептора 7
EP3494991A4 (en) COMPOSITION FOR PREVENTING OR TREATING DISEASES RELATING TO IL-8
BR112017002873A8 (pt) Processo para preparar intermediários sintéticos para preparar derivados de tetra-hidroquinolina
PH12016501441A1 (en) Chimeric alkaline phosphate-like proteins
BR112013027774A2 (pt) novos compostos como moduladores de proteína quinases
EP3157531A4 (en) Methods and compositions for stimulation of the intestinal enteroendocrine system for treating diseases or conditions related to the same
EP3122782A4 (en) Compositions and methods for treatment of diabetic macular edema
BR112017010311A2 (pt) 4-oxo-3,4-dihidro-1,2,3-benzotriazinas como moduladores de gpr139
BR112017009545A2 (pt) composição antibacteriana, método para a preparação de uma composição, bacteriófago, ácido nucleico isolado, polipeptídeo isolado, e uso de um bacteriófago, ácido nucleico ou polipeptídeo
BR112016009062A2 (pt) Composição antibacteriana, método para a preparação de uma composição, método para prever ou determinar a eficácia de uma terapia de bacteriófago em um indivíduo, método para selecionar um indivíduo ou determinar se um indivíduo é susceptível de se beneficiar de uma terapia com bacteriófagos, bacteriófago, ácido nucleico isolado, e, polipeptídeo isolado
EP3288565A4 (en) EXTRACELLULAR MATRIX COMPOSITIONS FOR THE TREATMENT OF CANCER OR IMMUNE DISEASES
EP3192524A4 (en) Hgf preparation suitable for treatment of nervous diseases
ZA201703467B (en) Methods of treating ocular conditions
EP3261652A4 (en) Extract of taiwanese propolis for treating ocular diseases
EA201791813A1 (ru) Применение выделенных фракций мастиковой смолы для лечения нейропатии зрительного нерва
EP3402511A4 (en) COMPOSITIONS AND METHODS FOR TREATING OCULAR DISEASES
EP3402531A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: AS CLASSIFICACOES ANTERIORES ERAM: C07D 215/42 , C07D 401/12

Ipc: C07D 215/42 (2006.01), C07D 401/12 (2006.01), A61K

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B25D Requested change of name of applicant approved

Owner name: NEWAMSTERDAM PHARMA B.V. (NL)

B25G Requested change of headquarter approved

Owner name: NEWAMSTERDAM PHARMA B.V. (NL)

B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 29/07/2015, OBSERVADAS AS CONDICOES LEGAIS